RBC Capital Reiterates Outperform on Spruce Biosciences, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an 'Outperform' rating on Spruce Biosciences (NASDAQ:SPRB), maintaining a price target of $8.
September 13, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital's reiteration of an 'Outperform' rating and maintenance of an $8 price target could positively influence Spruce Biosciences' stock in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. RBC Capital's reiteration of an 'Outperform' rating and maintenance of an $8 price target for Spruce Biosciences indicates a positive outlook for the company, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100